25. 進行性多巣性白質脳症
［臨床試験数：23，薬物数：33（DrugBank：20），標的遺伝子数：7，標的パスウェイ数：36］
Searched query = "Progressive multifocal leukoencephalopathy", "PML", "Leukoencephalopathy, progressive multifocal"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04453917 (ClinicalTrials.gov) | December 31, 2020 | 3/6/2020 | Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy | Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy | Progressive Multifocal Leukoencephalopathy | Biological: Collection of blood and urine;Biological: Spinal tap;Diagnostic Test: Brain MRI;Biological: Neurological evaluation | University Hospital, Toulouse | NULL | Not yet recruiting | 18 Years | N/A | All | 15 | N/A | France |
| 2 | NCT04091932 (ClinicalTrials.gov) | August 20, 2019 | 15/9/2019 | Treatment of PD-1 Inhibitor in AIDS-associated PML | The Effect and Safety of Programmed Cell Death Protein 1 (PD-1) Inhibitor on AIDS Patients With Progressive Multifocal Leukoencephalopathy (PML): A One-center, Single-arm and Prospective Study | Progressive Multifocal Leukoencephalopathy;AIDS | Drug: Pembrolizumab | First Affiliated Hospital of Zhejiang University | NULL | Recruiting | 18 Years | 65 Years | All | 10 | Phase 2 | China |
| 3 | NCT03399981 (ClinicalTrials.gov) | January 24, 2018 | 9/1/2018 | Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries | An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri | Progressive Multifocal Leukoencephalopathy | Biological: Tysabri | Biogen | NULL | Active, not recruiting | N/A | N/A | All | 72600 | United States | |
| 4 | JPRN-UMIN000022151 | 2016/04/30 | 30/04/2016 | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths | Department of Neurology, Shimane University Hospital | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan |
| 5 | JPRN-UMIN000023752 | 2016/04/14 | 24/08/2016 | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance | progressive multifocal leukoencephalopathy | Oral mefloquine hydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week oral intake until 6 months | Nagoya City University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 1 | Not applicable | Japan | |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT02694783 (ClinicalTrials.gov) | March 28, 2016 | 27/2/2016 | Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells | A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells | Progressive Multifocal Leukoencephalopathy | Biological: PyVST | National Institute of Neurological Disorders and Stroke (NINDS) | NULL | Completed | 18 Years | N/A | All | 60 | Early Phase 1 | United States |
| 7 | NCT01970410 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | Sub-Study: Analysis of JCV Antibody Index in MS Patients Treated With Teriflunomide - SWITCH-JCV | Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? (Sub-study: SWITCH-JCV) | Multiple Sclerosis | Drug: teriflunomide | Providence Health & Services | Multiple Sclerosis Center of Northeastern New York | Recruiting | 21 Years | 60 Years | All | 70 | Phase 4 | United States |
| 8 | EUCTR2012-000725-41-GB (EUCTR) | 22/01/2013 | 04/09/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 INN or Proposed INN: N/A Other descriptive name: Recombinant human interleukin-7 | Cytheris S.A. | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 2b | United States;European Union;Spain;Italy;Switzerland;United Kingdom | ||
| 9 | EUCTR2012-000725-41-ES (EUCTR) | 12/12/2012 | 14/09/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy. - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 15.0;Level: PT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 INN or Proposed INN: N/A Other descriptive name: Recombinant human interleukin-7 | Cytheris S.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 57 | Phase 2b | United States;European Union;Spain;United Kingdom;Switzerland | ||
| 10 | EUCTR2012-000725-41-IT (EUCTR) | 08/11/2012 | 11/12/2012 | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy | A randomized, placebo controlled, multicenter phase IIb study of human recombinant Interleukin-7 (CYT107) in HIV-related Progressive Multifocal Leukoencephalopathy - INVICTUS | HIV-infected patients with Progressive Multifocal Leukoencephalopathy MedDRA version: 14.1;Level: SOC;Classification code 10021881;Term: Infections and infestations;System Organ Class: 10021881 - Infections and infestations;Therapeutic area: Diseases [C] - Virus Diseases [C02] | Product Name: Recombinant human interleukin-7 Product Code: CYT107 Other descriptive name: Recombinant human interleukin-7 | CYTHERIS | NULL | Not Recruiting | Female: yes Male: yes | 57 | Phase 2b | United States;Spain;United Kingdom;Switzerland;Italy | ||
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2010-020369-26-DE (EUCTR) | 29/11/2010 | 18/08/2010 | High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab | High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab | Immune Reconstitution Inflammatory Syndrome MedDRA version: 12.1;Level: PT;Classification code 10054014;Term: Immune reconstitution syndrome | Product Name: methylprednisolone INN or Proposed INN: METHYLPREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE Product Name: prednisolone INN or Proposed INN: PREDNISOLONE | Biogen Idec | NULL | Not Recruiting | Female: yes Male: yes | 20 | Germany | |||
| 12 | NCT01211665 (ClinicalTrials.gov) | September 2010 | 29/7/2010 | Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS) | High-Dose Corticosteroids for Immune Reconstitution Inflammatory Syndrome in Patients Who Develop Progressive Multifocal Leukoencephalopathy on Natalizumab | Immune Reconstitution Inflammatory Syndrome;Leukoencephalopathy, Progressive Multifocal | Drug: Methylprednisolone;Drug: Prednisolone | Biogen | Elan Pharmaceuticals | Terminated | 18 Years | N/A | All | 3 | Phase 4 | United States;Germany |
| 13 | EUCTR2008-001314-24-IT (EUCTR) | 15/01/2009 | 19/03/2009 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam INN or Proposed INN: Mefloquine | BIOGEN IDEC LTD | NULL | Not Recruiting | Female: yes Male: yes | 40 | United Kingdom;France;Spain;Italy | |||
| 14 | EUCTR2008-001314-24-GB (EUCTR) | 02/01/2009 | 28/05/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;France;Spain;Italy | |||
| 15 | NCT00746941 (ClinicalTrials.gov) | January 2009 | 3/9/2008 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy | Drug: mefloquine | Biogen | Elan Pharmaceuticals | Terminated | 18 Years | 75 Years | All | 37 | Phase 1;Phase 2 | United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | EUCTR2008-001314-24-ES (EUCTR) | 19/11/2008 | 11/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) | Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | United Kingdom;France;Spain;Italy | |||
| 17 | EUCTR2008-001314-24-FR (EUCTR) | 22/10/2008 | 23/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 40 | United Kingdom;France;Spain;Italy | |||
| 18 | NCT00120367 (ClinicalTrials.gov) | April 2005 | 11/7/2005 | Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125) | Early Intensification of Combination Antiretroviral Therapy Including FUZEON® in the Treatment of Progressive Multifocal Leucoencephalopathy During HIV-1 Infection ANRS 125 Trial | Leukoencephalopathy, Progressive Multifocal;HIV Infections | Drug: Enfuvirtide;Drug: Tenofovir-Emtricitabine | French National Agency for Research on AIDS and Viral Hepatitis | Hoffmann-La Roche;Gilead Sciences | Completed | 18 Years | N/A | Both | 30 | Phase 2 | France |
| 19 | NCT00000945 (ClinicalTrials.gov) | November 1999 | 2/11/1999 | A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients | A Pilot Study of the Effect of Cidofovir for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Subjects With Acquired Immunodeficiency Syndrome (AIDS) | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Cidofovir;Drug: Probenecid | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | 18 Years | N/A | Both | 24 | N/A | United States |
| 20 | NCT00001048 (ClinicalTrials.gov) | February 1998 | 2/11/1999 | Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients | A Phase II Multicenter Study Comparing Antiretroviral Therapy Alone to Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in Human Immunodeficiency Virus (HIV)-Infected Subjects | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Filgrastim;Drug: Cytarabine;Drug: Zidovudine;Drug: Zalcitabine;Drug: Didanosine | National Institute of Allergy and Infectious Diseases (NIAID) | Bristol-Myers Squibb;Upjohn | Completed | 18 Years | 65 Years | Both | 90 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT00002270 (ClinicalTrials.gov) | October 1997 | 2/11/1999 | A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection | A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Interferon alfa-2b;Drug: Zidovudine | University of Miami | NULL | Completed | 18 Years | 65 Years | Both | N/A | United States | |
| 22 | NCT00002274 (ClinicalTrials.gov) | October 1997 | 2/11/1999 | A Study of ddI in Patients With AIDS Who Become Sicker While Taking Zidovudine | An Open Label Study Regimen of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) Exhibiting Significant Deterioration While Taking Zidovudine (Retrovir) | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Didanosine | Bristol-Myers Squibb | NULL | Completed | 12 Years | N/A | Both | N/A | United States | |
| 23 | NCT00002395 (ClinicalTrials.gov) | June 1996 | 2/11/1999 | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) | An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy | HIV Infections;Leukoencephalopathy, Progressive Multifocal | Drug: Topotecan | SmithKline Beecham | NULL | Completed | 18 Years | N/A | Both | 54 | Phase 2 | United States |